AstraZeneca Says Phase 3 Trial of Fasenra in COPD Fails to Meet Primary Endpoint
MT Newswires Live
Yesterday
AstraZeneca (AZN) said Wednesday that a phase 3 trial of its asthma treatment Fasenra in patients with chronic obstructive pulmonary disease, or COPD, did not meet the primary endpoint despite showing numerical improvement.
The company said Fasenra's safety and tolerability in the trial was consistent with the known profile of the drug, which is currently approved as an add-on maintenance medicine for severe eosinophilic asthma.
AstraZeneca said it will analyze the full data set from the trial and share the findings with the scientific community.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.